Hansoh Pharmaceutical Group Co Limited/ADR
HNPHYNext catalyst
Almonertinib
Lung Cancer
Get an email about HNPHY's next catalysts
Track Hansoh Pharmaceutical Group Co Limited/ADR (HNPHY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 4 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
5 upcoming, 0 past
Almonertinib Phase 3 Est. Readout (APPROACH)
Estimated primary completion for Almonertinib trial (NCT04841811) in Lung Cancer. Topline data typically follows completion by weeks to months.
SourceHS-20137 Phase 2 Est. Readout
Estimated primary completion for HS-20137 trial (NCT07879885) in Moderate-to-severe Plaque Psoriasis. Topline data typically follows completion by weeks to months.
SourceHS-20089 Phase 3 Est. Readout
Primary completion for HS-20089 trial (NCT06855069) in Ovarian Cancer
SourceHS-10542 Phase 2 Est. Readout
Primary completion for HS-10542 trial (NCT07470762) in Paroxysmal Nocturnal Hemoglobinuria
SourceHS-10516 + Lenvatinib Phase 2 Est. Readout
Primary completion for HS-10516 + Lenvatinib trial (NCT07097935) in Advanced Clear Cell Renal Cell Carcinoma
SourceMarket Overview
Stock performance and key metrics
HS-10504
Advanced or Metastatic NSCLC
HS-20093
Metastasis Castration Resistant Prostate Cancer(mCRPC)
Gemcitabine combined with docetaxel
Osteosarcoma
Aumolertinib
Non-small Cell Lung Cancer
Flumatinib
CML, CML-CP,MMR,TKI
HS-20117
Non-Squamous Non-Small Cell Lung Cancer
HS-10234
Chronic HBV Infection
HS-20094 injection
Overweight
Pegol-Sihematide
Chronic Kidney Diseases
Almonertinib
Lung Cancer
Topotecan
Small Cell Lung Cancer
TDF
Chronic HBV Infection
HS-10380 High Dose
SCHIZOPHRENIA 1 (Disorder)
Adebrelimab Injection
Non-Small Cell Lung Cancer
iloperidone
Schizophrenia
HS-20110+ Bevacizumab+5-FU/leucovorin
CRC
HS-10380 Low Dose
SCHIZOPHRENIA 1 (Disorder)
HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin
CRC
HS-20094
Overweight and Obesity
HS-20093 for Injection
Non-Small Cell Lung Cancer
HS-10542
Paroxysmal Nocturnal Hemoglobinuria
HS-10566
High-risk Non-muscle-invasive Bladder Cancer
HS-20089
Ovarian Cancer
PEG-Tα1
Hepatitis B, Chronic
HS-20137
Moderate-to-severe Plaque Psoriasis
HS-10374
Psoriatic Arthritis
HS-10516 + Lenvatinib
Advanced Clear Cell Renal Cell Carcinoma
HS-10370
Advanced Solid Tumor
HS-20110+Bevacizumab+Oxaliplatin+Capecitabine
CRC
HS-10380 Medium dose
SCHIZOPHRENIA 1 (Disorder)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HS-10504 | Phase 3 | Advanced or Metastatic NSCLC | - | - |
HS-20093 | Phase 3 | Metastasis Castration Resistant Prostate Cancer(mCRPC) | - | - |
Gemcitabine combined with docetaxel | Phase 3 | Osteosarcoma | - | - |
Aumolertinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
Flumatinib | Phase 3 | CML, CML-CP,MMR,TKI | - | - |
HS-20117 | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
HS-10234 | Phase 3 | Chronic HBV Infection | - | - |
HS-20094 injection | Phase 3 | Overweight | - | - |
Pegol-Sihematide | Phase 3 | Chronic Kidney Diseases | - | - |
Almonertinib | Phase 3 | Lung Cancer | - | - |
Topotecan | Phase 3 | Small Cell Lung Cancer | - | - |
TDF | Phase 3 | Chronic HBV Infection | - | - |
HS-10380 High Dose | Phase 2 | SCHIZOPHRENIA 1 (Disorder) | - | - |
Adebrelimab Injection | Phase 2 | Non-Small Cell Lung Cancer | - | - |
iloperidone | Phase 2 | Schizophrenia | - | - |
HS-20110+ Bevacizumab+5-FU/leucovorin | Phase 2 | CRC | - | - |
HS-10380 Low Dose | Phase 2 | SCHIZOPHRENIA 1 (Disorder) | - | - |
HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin | Phase 2 | CRC | - | - |
HS-20094 | Phase 2 | Overweight and Obesity | - | - |
HS-20093 for Injection | Phase 2 | Non-Small Cell Lung Cancer | - | - |
HS-10542 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
HS-10566 | Phase 2 | High-risk Non-muscle-invasive Bladder Cancer | - | - |
HS-20089 | Phase 2 | Ovarian Cancer | - | - |
PEG-Tα1 | Phase 2 | Hepatitis B, Chronic | - | - |
HS-20137 | Phase 2 | Moderate-to-severe Plaque Psoriasis | - | - |
HS-10374 | Phase 2 | Psoriatic Arthritis | - | - |
HS-10516 + Lenvatinib | Phase 2 | Advanced Clear Cell Renal Cell Carcinoma | - | - |
HS-10370 | Phase 2 | Advanced Solid Tumor | - | - |
HS-20110+Bevacizumab+Oxaliplatin+Capecitabine | Phase 2 | CRC | - | - |
HS-10380 Medium dose | Phase 2 | SCHIZOPHRENIA 1 (Disorder) | - | - |
weight loss
2 drugs in this indication
small cell lung cancer
1 drug in this indication
obesity/diabetes
1 drug in this indication
weight management/body weight regulation
1 drug in this indication
obesity
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Hansoh Pharmaceutical Group Co Limited/ADR's drug pipeline?→
CatalystAlert tracks 30 drug candidates in Hansoh Pharmaceutical Group Co Limited/ADR's (HNPHY) pipeline across Phase 3, Phase 2. Its lead program is Almonertinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hansoh Pharmaceutical Group Co Limited/ADR's next FDA catalyst?→
Hansoh Pharmaceutical Group Co Limited/ADR's (HNPHY) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HNPHY biotech catalysts?→
Add HNPHY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hansoh Pharmaceutical Group Co Limited/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.